StreetInsider.com News Articles

Form 6-K Ascendis Pharma A/S For: Oct 16

Fri, 16 Oct 2026 14:59:00 -0400

si-local-file:///var/storage/secattach/20261016/27197668.html

EU panel recommends Ascendis Pharma's navepegritide for achondroplasia

Fri, 16 Oct 2026 08:30:03 -0400

Ascendis Pharma A/S (Nasdaq: ASND) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion recommending marketing authorization for TransCon CNP (navepegritide) in the European Union.

The once-weekly treatment is intended for children two years of age and older with achondroplasia whose epiphyses are not closed. A final decision from the European Commission is expected in the fourth quarter of 2026.

The CHMP opinion was based on a review that included data from three randomized, double-blind, placebo-controlled clinical trials and up to three years of open-label extension data. Pivotal trial data

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Fri, 16 Oct 2026 08:29:00 -0400

COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not closed. The final European Commission (EC) decision on Ascendis Pharma’s Marketing Authorisation Application (MAA) is expected during Q4 2026.

“We are pleased to receive this positive opinion reflecting the unique profile of

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Fri, 16 Oct 2026 08:29:00 -0400

“We are pleased to receive this positive opinion reflecting the unique profile of

Ascendis Pharma (ASND) PT Lowered to $269 at UBS

Thu, 15 Oct 2026 09:21:51 -0400

UBS analyst Joon Lee lowered the price target on Ascendis Pharma (NASDAQ: ASND) to $269.00 (from $307.00) while maintaining a Buy rating.

Form 6-K Ascendis Pharma A/S For: Oct 14

Wed, 14 Oct 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20261014/27187806.html

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Tue, 06 Oct 2026 09:15:00 -0400

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of bone mass and microarchitecture in clinical trial patients treated with TransCon® PTH (palopegteriparatide) over a 5-year period.

“Our growing body

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

Tue, 06 Oct 2026 09:15:00 -0400

“Our growing body

Form 6-K Ascendis Pharma A/S For: Sep 29

Tue, 29 Sep 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260929/27122359.html

Form 4 Ascendis Pharma A/S For: Apr 14 Filed by: BIENAIME JEAN JACQUES

Mon, 28 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260928/27114526.html

H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)

Wed, 16 Sep 2026 06:55:13 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $344.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented: "On September 14, Ascendis announced that rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon semaglutide, will revert to Ascendis following termination of its Novo Nordisk—now simply Novo (NVO; not rated)—collaboration. Neither party will have continuing financial obligations to the other. We view the loss of partner-funded development and Novo’s cardiometabolic capabilities as the principal setback. The announcement does not disclose the reason for termination or new efficacy or safety findings, so we would not

Ascendis Pharma (ASND) call put ratio 1 call to 1 put a share price down 12.6%

Tue, 15 Sep 2026 13:57:38 -0400

Ascendis Pharma (NASDAQ: ASND) 30-day call option implied volatility is 42; compared to its 52-week range of 32 to 66. Call put ratio 1 call to 1 put a share price down 12.6%.

Form 6-K Ascendis Pharma A/S For: Sep 14

Tue, 15 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260915/27060513.html

Form 6-K Ascendis Pharma A/S For: Sep 14

Tue, 15 Sep 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20260915/27060514.html

Raymond James Downgrades Ascendis Pharma (ASND) to Outperform

Tue, 15 Sep 2026 03:25:35 -0400

Raymond James analyst Martin Auster downgraded Ascendis Pharma (NASDAQ: ASND) from Strong Buy to Outperform with a price target of $287.00.

The analyst comments: “Monday evening, ASND announced that it will regain rights on TransCon metabolic and cardiovascular programs from NVO and plans to develop multiple programs in these settings. Alongside this news, ASND announced a $400M share repurchase program. We are downgrading ASND from Strong Buy to Outperform and maintaining our $287 target price. While we continue to see ASND’s commercial portfolio and platform maintaining high long-term strategic value, our investor conversations over the past year suggested that optionality around

Raymond James Downgrades Ascendis Pharma (ASND) to Outperform

Tue, 15 Sep 2026 03:25:35 -0400

Raymond James analyst Martin Auster downgraded Ascendis Pharma (NASDAQ: ASND) from Strong Buy to Outperform with a price target of $287.00.

Ascendis Pharma board approves $400M share repurchase program

Mon, 14 Sep 2026 18:00:11 -0400

Ascendis Pharma A/S (Nasdaq: ASND) announced that its Board of Directors has authorized a share repurchase program of up to $400 million of the company's ordinary shares, according to a press release dated Sept. 14, 2026.

Purchases under the program may be executed through a variety of methods, including open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, and purchases through 10b5-1 trading plans, or a combination of these methods.

The timing and amount of any repurchases will be determined based on market conditions, share price, and other factors. The program does not obligate the company to repurchase any

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Mon, 14 Sep 2026 18:00:00 -0400

- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis
- Ascendis to initiate multiple programs in metabolic and cardiovascular diseases, including obesity

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it will regain the exclusive rights to develop, manufacture, and commercialize TransCon technology-based products in metabolic and cardiovascular diseases, including obesity. This follows termination of the collaboration agreement between Ascendis and Novo Nordisk A/S announced in November 2024. Under the terms of the agreement, following termination all licenses

Ascendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular Diseases

Mon, 14 Sep 2026 18:00:00 -0400

Ascendis Announces Planned $400 Million Share Repurchase Program

Mon, 14 Sep 2026 18:00:00 -0400

COPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s ordinary shares (the Share Repurchase Program).

Purchases under the planned Share Repurchase Program may be made from time to time, in such amounts as management deems appropriate, through a variety of methods, which may include open market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, purchases through 10b5-1 trading plans, or by any combination of such methods. The timing and amount of

Ascendis Announces Planned $400 Million Share Repurchase Program

Mon, 14 Sep 2026 18:00:00 -0400

H.C. Wainwright Reiterates Buy Rating on Ascendis Pharma (ASND)

Thu, 10 Sep 2026 06:48:59 -0400

H.C. Wainwright analyst Mitchell S. Kapoor reiterated a Buy rating and $344.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst commented: "Ascendis reported Week 52 data from seven treatment-naïve infants with achondroplasia (ACH), mean age 11.7 months, treated with once-weekly YUVIWEL (navepegritide) 100μg/kg/week: annualized growth velocity (AGV) was 9.9 cm/year, ACH-specific supine-length Z-score increased 0.42, Achondroplasia Foramen Magnum Score (AFMS) was stable or improved in 7/7, and mean sagittal foramen magnum diameter increased 3.15 mm. No decompression surgeries occurred. Pharmacokinetic (PK) profile was comparable to that seen in older children, with no treatment-related AEs or symptomatic hypotension reported through 52

TD Cowen on Ascendis Pharma (ASND): 'encouraging'

Thu, 10 Sep 2026 05:05:59 -0400

TD Cowen analyst Yaron Werber reiterated a Buy rating and $341.00 price target on Ascendis Pharma (NASDAQ: ASND).

The analyst comments "We view the first infant data for Yuviwel (SC QW) as encouraging given Ph2 reACHin is assessing a high-need complication beyond linear growth: foramen magnum stenosis. All 7 infants had stable or improved Achondroplasia Foramen Magnum Scores (AFMS) through Week 52, and no decompression surgeries occurred. Growth was also encouraging and more or less on par with BioMarin's (BMRN, Buy, $64.41; Nadeau) Voxzogo Ph2 data in 0 to <5y/o. However, this is a small, open-label sentinel cohort without a control

BMO Capital Reiterates Outperform Rating on Ascendis Pharma (ASND)

Thu, 10 Sep 2026 02:56:24 -0400

BMO Capital analyst David Lebowitz reiterated an Outperform rating and $319.00 price target on Ascendis Pharma (NASDAQ: ASND)

The analyst comments: “ASND presented infant data from the Phase 2 reACHin sentinel cohort at ESPE 2026, demonstrating benefits in linear growth and craniocervical junction health, with favorable safety. Despite the limited cohort size and an efficacy profile largely similar to Voxzogo, today’s data confirm TransCon CNP’s favorable profile in infants and support the ongoing RCT portion of reACHin for label expansion into <2yo infants. With its convenient weekly dosing schedule, we continue to expect Yuviwel to gradually emerge as the market leader

Ascendis Pharma reports 52-week infant data for TransCon CNP trial

Wed, 09 Sep 2026 16:02:35 -0400

Ascendis Pharma A/S (Nasdaq: ASND) released Week 52 data from the open-label sentinel cohort of its reACHin Trial, showing that once-weekly TransCon CNP (navepegritide) stabilized or improved foramen magnum stenosis and supported linear growth in infants aged 0 to under 2 years with achondroplasia. The data were presented at the annual meeting of the European Society for Paediatric Endocrinology (ESPE 2026).

The sentinel cohort enrolled seven infants with a mean age of 11.7 months prior to the double-blind portion of the trial. All children showed stable or improved Achondroplasia Foramen Magnum Score between baseline and Week 52. The mean change from